Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting

– Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

– Additional clinical data update from APEX Part 1 in patients with Advanced Systemic Mastocytosis (AdvSM) also to be reviewed

WALTHAM, Mass. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held Monday, December 11, 2023 at 8:00 a.m. ET (5:00 a.m. PT). The SUMMIT data are being presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on December 9, 2023 at 1:30 p.m. ET (10:30 a.m. PT), and the APEX data are being presented in a poster session on December 11, 2023.

The webcast event will be led by Andrew Robbins, Cogent’s President and Chief Executive Officer and will include a SUMMIT data presentation by PD Dr. Frank Siebenhaar, M.D., Head University Outpatient Clinic, Institute of Allergology, Charité – Universitätsmedizin Berlin and an APEX data presentation by Pankit Vachhani, M.D., assistant professor in the University of Alabama at Birmingham Department of Medicine, Division of Hematology and Oncology.

The live webcast can be accessed on the Investors and Media page of Cogent’s website at investors.cogentbio.com/events. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Ka (genes/pathways). Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653